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bjectives The aim of this study was to evaluate the beneﬁts of sirolimus-eluting stents (SES) and paclitaxel-
luting stents (PES) as compared with bare-metal stents (BMS) in patients undergoing primary angioplasty.
ackground Recent concerns have emerged on the potential higher risk of stent thrombosis after drug-
luting stent implantation, especially among ST-segment elevation myocardial infarction (STEMI) patients.
ethods We randomly assigned STEMI patients admitted within 12 h of symptom onset undergo-
ng primary angioplasty and stent implantation to BMS, PES, or SES. The primary study end point
as target lesion revascularization at 1-year follow-up. All patients were reviewed at our outpatient
linic or by telephone interview at 6, 12, and 24 months.
esults From October 2003 to December 2005, 270 STEMI patients undergoing primary angioplasty
ere randomized to BMS (n  90), PES (n  90), or SES (n  90). No patient was lost to follow-up.
s compared with BMS (14.4%), both PES (4.4%, p  0.023) and SES (3.3%, p  0.016) were associ-
ted with a signiﬁcant reduction in target lesion revascularization at 1-year follow-up. At 2-year fol-
ow-up no difference was observed in terms of death, reinfarction, and combined death and/or rein-
arction, but as compared with BMS, both PES and SES were associated with signiﬁcant beneﬁts in
ajor adverse cardiac events (PES: 16.7%, p  0.015; SES: 15.6%, p  0.009, respectively).
onclusions This study shows that among STEMI patients undergoing primary angioplasty, both
ES and PES are safe and associated with signiﬁcant beneﬁts in terms of target lesion revasculariza-
ion up to the 2-year follow-up. Thus, until the results of further large randomized trials with long-
erm follow-up become available, drug-eluting stents may be considered for STEMI patients under-
oing primary angioplasty. (PaclitAxel or Sirolimus-Eluting Stent versus Bare Metal Stent in Primary
ngioplasty [PASEO] Randomized Trial; NCT00759850) (J Am Coll Cardiol Intv 2009;2:515–23)
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516rimary percutaneous coronary intervention (PCI), when
erformed expeditiously and expertly, has been shown to be
uperior to thrombolytic therapy in the treatment of patients
ith ST-segment elevation myocardial infarction (STEMI)
1). Although, as compared with balloon angioplasty, stent
mplantation has reduced the occurrence of restenosis in
elected STEMI patients (2,3), the outcome of bare-metal
tents (BMS) seem to be worse in unselected patients with
rate of target vessel revascularization (TVR) up to 20%
4,5). Several randomized trials have shown that drug-
luting stents (DES), compared with BMS, are associated
ith a significant reduction in restenosis and TVR in
lective patients (6–10). However, recent concerns have
merged on the potential higher risk of stent thrombosis
ith DES (11–14) that might be even more pronounced
mong STEMI patients, as suggested by a prospective
egistry (15). The aim of the current study was to evaluate
he benefits of sirolimus-eluting stents (SES) and paclitaxel-
eluting stents (PES) as com-
pared with the benefits of BMS
in patients undergoing primary
angioplasty for STEMI.
Methods
The PASEO (PaclitAxel or
Sirolimus-Eluting Stent versus
Bare Metal Stent in Primary
Angioplasty) trial was a prospec-
tive, single-center, randomized
trial evaluating the benefits of
SES or PES as compared with
BMS implantation in patients
undergoing primary angioplasty
for acute STEMI. Individuals
eligible for enrollment were pa-
ients presenting with STEMI who fulfilled all the follow-
ng inclusion criteria: 1) chest pain for more than 30 min;
) ST-segment elevation of 1 mm or more in 2 or more
ontiguous electrocardiograph leads or with presumably new
eft bundle branch block; 3) hospital admission within 12 h
rom symptoms onset. Exclusion criteria included: 1) active
nternal bleeding or a history of bleeding diathesis within
he previous 30 days; 2) history of intracranial hemorrhage,
ntracranial neoplasm, arteriovenous malformation or aneu-
ysm; 3) known allergy to sirolimus, paclitaxel, heparin,
spirin, or clopidogrel; 4) history of stroke within 30 days or
ny history of hemorrhagic stroke; 5) major surgical proce-
ure or severe physical trauma within the previous month;
) history, symptoms, or findings suggestive of aortic
issection; 7) thrombolytic/fibrinolytic therapy within 24 h;
) history of thrombocytopenia; 9) hemorrhagic retinopa-
hy; 10) patients on warfarin or acenocoumarol with inter-
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
CI  percutaneous
oronary intervention
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)
TEMI  ST-segment
levation myocardial
nfarction
LR  target lesion
evascularization
VR  target vessel
evascularizationational normalized ratio 2; and 11) pregnancy. Previous oastrointestinal ulcer or gastrointestinal bleeding were not
xclusion criteria. A vessel size 2.25 mm was the only
ngiographic exclusion criteria.
The institutional review board of the Ospedale “S.G.
oscati” (Avellino, Italy) approved the protocol in 2003,
nd all patients gave written informed consent.
Open-label randomization was performed in the cathe-
erization laboratory after initial angiography by the treating
hysician when eligibility criteria were met. A 1:1:1
omputer-generated random sequence, without blocking or
tratification, was used. Sealed envelopes indicated the
reatment group to which the patients were assigned: SES,
ES, or BMS.
edications. In the coronary care unit, all patients received
0 U/kg intravenous bolus of unfractionated heparin plus
000 U/h infusion (to maintain an activated clotting time of
t least 200 s), aspirin intravenously (500 mg), and clopi-
ogrel (300-mg loading dose). All patients received up-
tream glycoprotein IIb/IIIa inhibitors as a routine adjunc-
ive therapy before primary PCI. Post-interventional
ntiplatelet therapy for all patients included in the 3 study
roups consisted of aspirin (100 mg) indefinitely and clopi-
ogrel (75 mg for 6 months).
ngioplasty procedure. Stenting procedures were per-
ormed according to standard techniques. The number, size,
nd length of stents (based on online quantitative angio-
raphic analyses), and the type of BMS to be implanted,
ere left to the operator’s discretion. In cases of DES
mplantation, it was recommended to cover the entire
ength of the lesion with additional coverage of 5 mm
roximal and distal to the lesion. The use of intravascular
ltrasound, adjunctive thrombectomy devices, distal protec-
ion devices, and intra-aortic balloon pump were left to the
perator’s discretion.
ngiographic analysis. Thrombolysis In Myocardial Infarc-
ion (TIMI) flow grade 3 coronary flow in the treated vessel
nd a residual stenosis less than 30% were the criteria used
o define a successful PCI. Offline quantitative coronary
ngiography (Integris Allura, Philips, Best, the Nether-
ands) were performed by 2 experienced technicians who
ere unaware of treatment assignment with the averaging
cores if they were not in agreement. The target lesion was
efined as the stented segment plus the 5-mm segments
mmediately proximal and distal to the stent.
ata collection and follow-up. All patients were reviewed at
ur outpatient clinic or by telephone interview at 6, 12, and
4 months. A stress test was performed at 6 to 8 months and
ubsequently yearly. For patients who died during follow-
p, hospital records and necropsy data were reviewed when
ossible. No patient was lost to follow-up.
tudy end points and deﬁnitions. The primary end point was
arget lesion revascularization (TLR) at 1-year follow-up.
econdary end points were: 1) cumulative combined incidence
f death and/or recurrent MI at 2-year follow-up; 2)
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517umulative incidence of in-stent thrombosis (assessed ac-
ording to Academic Research Consortium’s definition
16]) at 2-year follow-up; and 3) major adverse cardiac
vents (combined death and/or recurrent MI and/or TLR)
t 2-year follow-up. All deaths were considered cardiac
nless an unequivocal noncardiac cause could be identified.
ecurrent MI was defined as recurrence of anginal symptoms
ith typical electrocardiographic changes and increase above
he upper limit of normal of creatine kinase-myocardial band
r troponin. The indication for a second intervention had to be
ubstantiated by symptoms or by electrocardiographic or scin-
igraphic evidence of ischemia at rest or during exercise.
ubsequent revascularization of other coronary arteries did not
onstitute an end point. All events were reviewed by 2
ardiologists blinded to treatment assignment.
tatistical analysis. Statistical analysis was performed using
PSS version 15.0 (SPSS Inc., Chicago, Illinois). Contin-
ous data were expressed as mean (SD) and categorical data
s percentages. Data were analyzed according to intention-
o-treat analysis (SES vs. BMS and PES vs. BMS). The
nalysis of variance or the Mann-Whitney U test were
ppropriately used for continuous variables. (Normal distri-
ution was assessed by the Kolmogorov-Smirnov test.) The
hi-square test or Fisher exact test was used for categorical
ariables The difference in event rates between groups
uring the follow-up period was assessed by the Kaplan-
eier method with the log-rank test. A probability value of
 0.025 (with Bonferroni correction) was considered
ignificant.
AMPLE SIZE CALCULATION. According to recent reports
4,5), we estimated a rate of TLR at 1 year of 20% in the
MS group. With an anticipated 2-sided test for differences
n independent binomial proportions at the 2.5% signifi-
ance level (with Bonferroni correction) with a power of
0%, 89 patients were necessary to detect a reduction in a
Figure 1. Study Flow Chart
The ﬁgure shows how patients were assigned to speciﬁc stent treatment grou
SES  sirolimus-eluting stent(s); STEMI  ST-segment elevation myocardial infrimary end point of 80% (from 20% to 4%) with DES oPES and SES, respectively). The number of patients was
xtended to 90 per group.
esults
atient population. From October 1, 2003, to December
1, 2005, 270 patients with STEMI undergoing primary
ngioplasty and stent implantation were randomized to
MS (n  90), PES (n  90), or SES (n  90) treatment.
trial flow diagram is shown in Figure 1. As reported in
ables 1 and 2, no difference was observed in terms of
aseline demographic, clinical, and angiographic character-
stics among the groups.
rocedural results. As shown in Table 2, no difference was
bserved in terms of angiographic and procedural charac-
eristics. Almost 50% of patients underwent PCI of left
nterior descending artery. All patients received upstream
lycoprotein IIb/IIIa inhibitors. Procedural success was
btained in 93% to 95% of patients. A direct stenting
trategy was adopted in 24% to 29% of patients. In the PES
roup, we observed a higher number of stents per patient
1.28  0.56 vs. 1.11  0.35, p  0.036).
linical outcome at 1-year follow-up. Follow-up data were
vailable for all patients. Almost all patients stopped clopi-
ogrel therapy at 6-month follow-up (Table 3). As reported
n Table 4, at 1-year follow-up, no difference was observed
n terms of death (6 deaths in BMS patients due to: heart
ailure [n  3], sudden death [n  1], reinfarction [n  1],
ardiac surgery [n  1]; 4 deaths in PES patients due to:
udden death [n 2], reinfarction [n 2]; 3 deaths in SES
atients due to: sudden death [n 2], reinfarction [n 1]),
einfarction, and combined death and/or reinfarction. One
tent thrombosis was documented in both the BMS (1.1%)
nd PES (1.1%) groups, both of them within 30 days from
rimary PCI, whereas no case of stent thrombosis was
S  bare-metal stent(s); PES  paclitaxel-eluting stent(s); pts  patients;
.ps. BMbserved after 30 days. As compared with BMS (14.4%),
b
i
(
a
s
b
t(s).
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 6 , 2 0 0 9
J U N E 2 0 0 9 : 5 1 5 – 2 3
Di Lorenzo et al.
DES in Primary Angioplasty
518oth PES (4.4%, hazard ratio [HR] [95% confidence
nterval (CI)]: 0.29 [0.095 to 0.89], p  0.023) and SES
3.3%, HR [95% CI]: 0.21 [0.06 to 0.75], p  0.016) were
Table 1. Baseline Demographic and Clinical Characteristics of the 3 Group
Variable BMS (n  90) PES (n 
Age, yrs 62  17 63  15
Male, % 71.1 68.9
Hypertension, % 24.4 26.7
Diabetes, % 25.6 23.3
IDDM 8.9 7.8
NIDDM 16.7 15.6
Smoking, % 26.7 24.4
Previous MI, % 12.2 14.4
Previous CABG, % 6.7 7.8
Previous PCI, % 4.4 3.3
Cardiogenic shock, % 15.6 16.7
Anterior MI, % 50 51.1
Ejection fraction 40%, % 36.7 38.9
Ischemia time, min 292  222 258  19
Door-to-balloon time, min 44.4  13.5 43.2  14
BMS  bare-metal stent(s); CABG  coronary artery bypass graft; IDDM  insulin-dependent di
paclitaxel-eluting stent(s); PCI percutaneous coronary intervention; SES sirolimus-eluting sten
Table 2. Angiographic and Procedural Characteristics of the 3 Groups of P
Variable BMS (n  90) PES
IRA, %
LAD 50
LCX 23.3
RCA 26.7
Pre-procedural TIMI ﬂow grade, %
0–1 75.6
2 11.1
3 13.3
Post-procedural TIMI ﬂow grade, %
0–1 1.1
2 3.3
3 95.6
RD, mm 3.13 0.51 3
% stenosis before 89.1 9.51 88
% stenosis after 6.9 5.6 6
Stent diameter, mm 3.12 0.46 3.1
Max stent diameter, mm 3.26 0.47 3.2
Total stent length, mm 20.25 5.6 21
Number of stents 1.11 0.35 1.2
1 stent, % 10
Direct stenting, % 26.7
Maximal balloon inﬂation, atm 15.7 4.74 16
Procedural success, % 95.6
GP IIb/IIIa inhibitors, % 100
Thrombectomy devices, % 4.4
GP glycoprotein; IRA infarct-related artery; LAD left anterior descending artery; LCX left ciInfarction; other abbreviations as in Table 1.ssociated with a significant reduction in TLR (primary
tudy end point). Finally, as compared with BMS (24.4%),
oth PES and SES were associated with significant benefits
atients
p Value SES (n  90) p Value
0.7 62  15 0.51
0.75 71.1 1.0
0.73 27.8 0.61
27.8
0.73 8.9 0.74
17.8
0.73 24.4 0.73
0.66 15.6 0.52
0.77 5.6 0.76
0.7 6.7 0.52
0.84 14.4 0.84
0.88 53.3 0.66
0.75 34.4 0.76
0.36 264  198 0.37
0.99 45.2  16.9 0.93
mellitus; MI  myocardial infarction; NIDDM  noninsulin-dependent diabetes mellitus; PES 
s
90) p Value SES (n  90) p Value
0.86 0.74
53.3
23.3
23.3
0.94 0.85
78.9
8.9
12.2
0.36 0.77
1.1
5.6
93.3
44 0.24 3.14 0.48 0.55
3 0.5 88.3 9.9 0.69
1 0.75 7.1 6.1 0.88
38 0.18 3.08 0.32 0.89
4 0.76 3.25 0.43 0.97
1 0.07 22.2 7.8 0.44
56 0.023 1.19 0.47 0.21
0.86 22.2 0.26
0.73 28.9 0.74
53 0.33 16.2 2.96 0.20
0.51 93.3 0.52
1.0 100 1.0
1.0 4.4 1.0
x artery; RCA right coronary artery; RD reference diameter; TIMI Thrombolysis In Myocardials of P
90)
2
.2
abetesatient
(n 
51.1
25.6
23.3
77.8
10
12.2
0
6.7
93.3
.2 0.
.1 9.
.6 6.
7 0.
7 0.
.8 7.
8 0.
15.6
24.4
.1 3.
93.3
100
4.4
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519n major adverse cardiac events (PES: 11.1%, HR [95% CI]:
.42 [0.2 to 0.9], p 0.02; SES: 11.1%, HR [95% CI]: 0.42
0.2 to 0.89], p  0.02).
linical outcome at 2-year follow-up. Follow-up data
ere available in all patients. As reported in Table 4, at
-year follow-up, no difference was observed in terms of
eath (Fig. 2) (9 deaths in BMS patients due to: heart
ailure [n  4], sudden death [n  2], cardiac surgery
n  1], reinfarction [n  2]; 6 deaths in PES patients
ue to: sudden death [n  2], reinfarction [n  2];
ardiogenic shock [n  2]; 5 deaths in SES patients due
o: sudden death [n  2], reinfarction [n  2], noncar-
iac death [n  1]), reinfarction (Fig. 3), and combined
eath and/or reinfarction (secondary study end point)
Table 3. Medical Therapy of the 3 Groups of Patients
Variable BMS (n  90) PES
Aspirin, % 100
Beta-blockers, % 95.6
ACE inhibitors, % 92.2
Statins, % 100
Clopidogrel at discharge, % 100
Clopidogrel administration, days 184  9 1
Clopidogrel at
30 days, % 100
6 months, % 60
ACE angiotensin-converting enzyme; other abbreviations as in Table 1.
Table 4. Clinical Outcome at 1-Year Follow-Up
Variable
BMS
(n  90)
PES
(n  90)
p Value
PES vs. BMS
1-year outcome
Death, % 6.7 4.4 0.52
reMI, % 6.7 3.3 0.30
Death and/or reMI, % 13.3 7.8 0.23
TLR, % 14.4 4.4 0.023
Deﬁnite IST, % 1.1 1.1 1.0
Early (30 days) 1.1 1.1 1.0
Late (30 days) 0 0 1.0
Total IST,* % 4.4 3.3 0.7
MACE, % 24.4 11.1 0.02
2-year outcome
Death 10 6.7 0.42
ReMI, % 11.1 5.6 0.17
Death and/or reMI, % 18.9 12.2 0.22
TLR, % 17.8 5.6 0.01
Deﬁnite IST, % 1.1 1.1 1.0
Very late IST (1 year) 0 0 1.0
Total IST* 6.7 5.6 0.74
MACE, % 32.2 16.7 0.015
*Definite, probable, and possible in-stent thrombosis.
CI confidence interval; HR hazard ratio; IST angiographic in-stent thrombosis; MACEmajin Table 1.PES: 12.2%, HR [95% CI]: 0.63 [0.29 to 1.34], p 
.17; SES: 11.1%, HR [95% CI]: 0.57 [0.26 to 1.23],
 0.27), as compared with BMS (18.3%) (Fig. 4). No
dditional case of in-stent thrombosis was observed up to
-year follow-up. As compared with BMS (17.8%), both
ES (5.6%, HR [95% CI]: 0.29 [0.11 to 0.8], p  0.01)
nd SES (4.4%, HR [95% CI]: 0.23 [0.076 to 0.68], p 
.004) were associated with a significant reduction in
LR (Fig. 5). Finally, as compared with BMS (32.2%),
oth PES and SES were associated with significant
enefits in overall MACE (secondary study end point)
PES: 16.7%, HR [95% CI]: 0.47 [0.25 to 0.88], p 
.015; SES: 15.6%, HR [95% CI]: 0.44 [0.23 to 0.83],
 0.005) (Fig. 6).
90) p Value SES (n  90) p Value
1.0 100 1.0
0.53 96.7 0.7
0.6 88.9 0.44
0.5 98.9 0.32
1.0 100 1.0
8 0.44 181  7 0.14
1.0 100 1.0
0.44 64.4 0.54
HR [95% CI]
SES
(n  90)
p Value
SES vs. BMS HR [95% CI]
0.66 [0.19–2.34] 3.3 0.3 0.49 [0.12–1.96]
0.49 [0.12–1.96] 4.4 0.45 0.65 [0.18–2.23]
0.57 [0.22–1.45] 7.8 0.49 0.57 [0.22–1.44]
0.29 [0.095–0.89] 3.3 0.016 0.21 [0.06–0.75]
0.5 [0.045–5.47] 0 0.61 0.0015 [0–147346]
0.5 [0.045–5.47] 0 0.61 0.0015 [0–147346]
— 0 1.0 —
0.76 [0.17–3.35] 2.2 0.41 0.49 [0.09–2.68]
0.42 [0.2–0.9] 11.1 0.02 0.42 [0.2–0.89]
0.66 [0.23–1.85] 5.6 0.26 0.54 [0.18–1.61]
0.8 [0.16–1.42] 6.7 0.27 0.58 [0.21–1.59]
0.63 [0.29–1.34] 11.1 0.14 0.57 [0.26–1.23]
0.29 [0.11–0.8] 4.4 0.004 0.23 [0.08–0.68]
0.5 [0.045–5.47] 0 0.61 0.015 [0–147346]
— 0 0 —
0.82 [0.25–2.69] 3.3 0.31 0.48 [0.12–1.94]
0.47 [0.25–0.88] 15.6 0.009 0.44 [0.23–0.83]
rse cardiac events; reMI reinfarction; TLR target lesion revascularization; other abbreviations as(n 
100
92.2
90
97.8
100
82 
100
65.6or adve
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520iscussion
o the best of our knowledge, this is the first randomized
tudy evaluating the benefits and safety of both PES and
ES versus BMS in patients undergoing primary angio-
lasty for STEMI at long-term follow-up (2 years). The
ain finding of the current study is that PES and SES are
afer and more effective than BMS, mainly due to a
eduction in TLR.
After the initial safety concerns, numerous studies and
andomized trials have demonstrated the safety and efficacy
f stenting in the setting of STEMI (3).
A recent comprehensive meta-analysis in patients under-
oing primary PCI has shown the benefits of stenting
ompared with balloon angioplasty alone in terms of reduc-
ng TVR, though no definite affect on death and reinfarc-
ion was present (3). However, restenosis rates after BMS in
TEMI patients are still high, especially in unselected
atients with complex lesion morphology (4,5). Several
andomized trials have shown that, among elective patients,
ES are associated with a significant reduction in restenosis
nd TVR (6–10). However, recent concerns have emerged
egarding an increased risk of late thrombosis stent associ-
ted with DES (12–15). As most episodes of stent throm-
osis result in MI, this increase with DES may impact
ortality, particularly after primary angioplasty, as reinfarc-
Figure 2. Kaplan-Meier Survival Curves for Death Comparing BMS, PES,
and SES
Kaplan-Meier survival curves comparing BMS with PES (p  0.84) and SES
(p  0.52). Abbreviations as in Figure 1.ion is a major determinant of survival (17). In a recentrospective multicenter primary angioplasty registry (PRE-
IER [Prospective Registry Evaluating Myocardial Infarc-
ion Events and Recovery]), the use of DES rather than
MS was associated with higher risk of mortality within the
rst 6 months (presumably due to higher stent thrombosis),
articularly in the case of early discontinuation of double
ral antiplatelet therapy (18). In fact, unlike with elective
atients, it may be difficult to forecast future long-term
atients’ compliance at the time of intervention among
TEMI patients (18).
Several randomized trials have been conducted so far in
TEMI (19–35). Valgimigli et al. (19) compared SES plus
irofiban with the bare-metal Bx Velocity (Cordis Corp.,
ridgewater, New Jersey) plus abciximab in 175 STEMI
atients. At 8-month follow-up, SES was associated with a
ignificant reduction in TVR (7% vs. 20%, p  0.01), with
similar outcome in terms of death (2% vs. 3%, p  NS),
einfarction (1% vs. 3%, p NS), and stent thrombosis (0%
s. 2%, p  NS). Similar benefits have been observed in the
arger MULTISTRATEGY (Multicentre Evaluation of
ingle High-Dose Bolus Tirofiban versus Abciximab with
irolimus-Eluting Stent or Bare Metal Stent in Acute
yocardial Infarction Study) trial (32). The benefits from
ES in terms of reducing clinical and angiographic reste-
osis without an increase in death or MI have been
onfirmed in subsequent moderate-sized randomized trials
Figure 3. Kaplan-Meier Event-Free Survival Curves for Reinfarction
Comparing BMS, PES, and SES
Kaplan-Meier event-free survival curves for reinfarction comparing BMS
with PES (p  0.34) and SES (p  0.58). Abbreviations as in Figure 1.
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521uch as the TYPHOON (Trial to Assess the Use of the
ypher Stent in Acute Myocardial Infarction Treated with
ngioplasty), SESAMI (Sirolimus-Eluting Stent Versus
are-Metal Stent in Acute Myocardial Infarction), and
ISSION trials (21,22,27).
In the PASSION (Paclitaxel-Eluting Stent versus Con-
entional Stent in ST-Segment Elevation Myocardial In-
arction ) trial (20), Laarman et al. compared PES versus
xpress (Boston Scientific, Natick, Massachusetts) stents in
19 STEMI patients. Despite the safety of PES in terms of
eath (4.6% vs. 6.5%, pNS) and stent thrombosis (1% vs.
%, p  NS) at 1-year follow-up, as compared with BMS,
nly a weak trend was present toward a reduction in TLR
5.3% vs. 7.8%, p  NS). The relatively less favorable
utcomes of PES in this trial compared with the outcomes
f SES in the previous trials may relate either to the less
arked reduction of neointimal hyperplasia with paclitaxel
ersus sirolimus, or a better outcome with the control stents
n the PASSION trial compared with the Bx Velocity stents
n the SES trials. Also of note, routine angiographic
ollow-up was not performed in the PASSION trial. In fact,
everal reports have demonstrated that routine angiographic
ollow-up is associated with a larger rate of TVR, even in
he era of DES (36). Similar findings have been observed in
he recently conducted large HORIZONS AMI (Harmo-
Figure 4. Kaplan-Meier Event-Free Survival Curves (for Death and/or
Reinfarction) Comparing BMS, PES, and SES
Kaplan-Meier event-free survival curves (for death and/or reinfarction) com-
paring BMS with PES (p  0.44) and SES (p  0.29). Abbreviations as in
Figure 1.izing Outcomes with Revascularization and Stents incute Myocardial Infarction) trial (32), including more
han 3,000 STEMI patients, that have shown significant
enefits in terms of TLR with Taxus (Boston Scientific)
tents as compared with BMS (4.5% vs. 7.5%, respectively),
ith similar outcome in terms of death and reinfarction.
However, almost all currently available trials have pro-
ided relatively short-term follow-up data (not longer than
2 months), whereas late stent thrombosis has been de-
cribed up to 1 to 2 years after clopidogrel discontinuation.
The STRATEGY (Single High-Dose Bolus Tirofiban
nd Sirolimus-Eluting Stent vs. Abciximab and Bare-Metal
tent in Myocardial Infarction) trial is the only trial pub-
ished so far with 2-year follow-up data, showing long-term
afety and benefits of SES as compared with BMS (33).
In our study, including a larger population, we demon-
trated the long-term safety and benefits of both SES and
ES as compared with BMS. Of relevance, unlike the vast
ajority of randomized trials so far conducted, in our trial,
he superiority of SES and PES was observed without use of
outine angiographic follow-up.
Large randomized trials, with longer follow-up data are
ertainly needed to further investigate the long-term safety
f DES in primary angioplasty. In this regard, important
nformation is expected to be derived from the HORIZONS-
MI trial (34).
Figure 5. Kaplan-Meier Event-Free Survival Curves for TLR Comparing
BMS, PES, and SES
Kaplan-Meier event-free survival curves for target lesion revascularization
(TLR) comparing BMS with PES (p  0.02) and SES (p  0.008). Abbrevia-
tions as in Figure 1.
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522tudy limitations. Due to a relatively late randomization
trategy (after initial angiography), patients have for the
ost part been selected, and thus the conclusion of this trial
annot be extended to all patients undergoing primary
ngioplasty for STEMI. Even though small vessels (2.25 to
.5 mm) were not excluded, our patient population had a
elatively larger (3.1 mm) mean reference diameters than
ere included in previous randomized trials. Furthermore,
o avoid any bias due to length of clopidogrel prescription,
e preferred to prescribe clopidogrel up to 6 months in
MS patients as well.
Despite long-term follow-up data, due to the relatively
mall sample size, this trial cannot provide definite conclu-
ions on DES safety in terms of death and reinfarction that
ill be hopefully provided by large randomized trials.
onclusions
his study shows that among STEMI patients undergoing
rimary angioplasty, both SES and PES are safe and
ssociated with significant benefits in terms of TLR up to
-year follow-up. Thus, until the results of further large
andomized trials with long-term follow-up become avail-
ble, DES may be considered for use for STEMI patients
Figure 6. Kaplan-Meier Event-Free Survival Curves for MACE Comparing
BMS, PES, and SES
Kaplan-Meier event-free survival curves for major adverse cardiac events
(MACE) comparing BMS with PES (p  0.03) and SES (p  0.018). Abbrevia-
tions as in Figure 1.ndergoing primary angioplasty.eprint requests and correspondence: Dr. Emilio Di Lorenzo,
ivision of Cardiology, Laboratory of Cardiac Catheterization and
nterventional Cardiology, S.G. Moscati Hospital, Via Otranto,
3100 Avellino, Italy. E-mail: emidilorenzo@tin.it.
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